The Relationship Of ARHI Gene Promoter Methylation With Ovarian Cancer

BackgroundThe incidence of ovarian cancer in the third non-benign gynecologic, but the survival rate was low. Deep in the pelvis due to ovarian position, the early symptoms of ovarian cancer patients are not typical, it is to discover and give effective treatment is very difficult, About60%～70%of patients with ovarian cancer has been diagnosed with advanced clinical. In recent years, studies of ovarian cancer has been the focal point of gynecological cancer research, Even after the efforts of countless people, making surgical continuously improved and developed a new type of chemotherapy drugs, summed up the more advanced chemotherapy. The improved quality of life to some extent, although advanced ovarian cancer patients, however, the5-year survival rate is still at25%～35%fluctuation. Today the etiology and mechanism of ovarian cancer is unclear, the lack of specific sensitive method for early diagnosis. Therefore, revealing the occurrence of ovarian cancer, the progress of the mechanism in its early diagnosis, timely and effective treatment is important.ARHI gene is now found in a closely related with gynecological tumors due to promoter methylation and inactivation of important tumor suppressor genes. In this study,15cases of normal ovarian tissue,15cases of benign ovarian tumor tissues using methylation PCR method,20cases of ovarian cancer ARHI gene promoter methylation detection, Immunohistochemical SP method for detecting the specimens of VEGF protein expression. To clarify ARHI methylation and gene expression mechanisms VEGF in ovarian cancer development, for the treatment of ovarian cancer nest to find a new spot. ObjectiveResearch-ARHI gene promoter methylation, the expression of VEGF protein expression in ovarian cancer, and to explore ARHI gene promoter methylation in ovarian cancer during the impact and significance of the formation.Methods1. Study Object:50cases of ovarian tissues fixed in wax were collected from the pathology department of The Puyang City People’s Hospital in May2009-June2013. It contains15cases of normal ovarian tissues (group A),15cases of benign ovarian tumor tissues (group B) and20cases of ovarian cancer tissues (13cases of serous capsule adenocarcinoma,7cases of mucinous capsule adenocarcinoma)(group C). The patient’s age ranged from20to65years, the median age is46years. All patients had not received chemotherapy and radiation before.15cases of normal ovarian tissues were moved out from the normol side of uterus and double accessories.2. Using immunohistochemical assay VEGF protein in normal ovarian tissue, benign ovarian tumors and ovarian cancer tissues circumstances. By MS-PCR method (methylation-specific polymerase chain reaction) to detect normal ovarian tissue, benign ovarian tumors and ovarian cancer ARHI gene promoter methylation.3. Statistical method:Statistical analysis was done using SPSS16.0. All immunohistochemical data is expressed as mean±standard deviation to analyze their normality and homogeneity of variance respectively, significant level being0.05.Results1. benign ovarian tumor tissue (group B), ovarian cancer (group C) in ARHI gene promoter methylation frequencies were:14.3%,75%. ovarian cancer tissues was significantly higher methylation benign ovarian tumor tissues, B, C difference between the two groups was statistically significant (χ2=12.126, P<0.05). 2. VEGF protein expression in normal ovarian tissue was negative; expressed in benign ovarian tumor tissues was weakly positive, the positive rate was7/15(46.7%); expression increased, the positive expression rate in ovarian cancer14/20(70.0%) was strongly positive.(χ2=24.126, P<0.001).Conclusion1. Ovarian cancer ARHI DNA methylation status of the promoter region of the gene, which may play an important role in the pathogenesis of ovarian cancer.2. Abnormally high expression of VEGF protein Involved in the development of ovarian cancer.